Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

5 terminated/withdrawn out of 20 trials

Success Rate

37.5%

-49.1% vs industry average

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

167%

5 of 3 completed trials have results

Key Signals

8 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

10(52.6%)

Phase 2

6(31.6%)

Phase 3

3(15.8%)

19Total

Phase 1(10)

Phase 2(6)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT06246149Phase 3Recruiting

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Role: collaborator

NCT06414590Phase 2Recruiting

Neoadjuvant Tebentafusp for Uveal Melanoma

Role: collaborator

NCT07493122Phase 1Not Yet Recruiting

Study of IMC-S118AI in Type 1 Diabetes

Role: lead

NCT03070392Phase 2Completed

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Role: lead

NCT04262466Phase 1Active Not Recruiting

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Role: lead

NCT06070012Phase 2Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Role: collaborator

NCT05549297Phase 3Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Role: lead

NCT06112314Phase 3Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Role: lead

NCT07156136Phase 1Recruiting

Study of IMC-P115C in Advanced PRAME-Positive Cancers

Role: lead

NCT06627244Phase 2Recruiting

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Role: collaborator

NCT06840119Phase 1Recruiting

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Role: lead

NCT05315258Phase 2Active Not Recruiting

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Role: collaborator

NCT03973333Phase 1Withdrawn

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Role: lead

NCT05867056Phase 1Withdrawn

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

Role: lead

NCT02535078Phase 1Withdrawn

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Role: lead

NCT02570308Phase 1Completed

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

Role: lead

NCT03515551Phase 1Terminated

Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

Role: lead

NCT04960891Unknown

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

Role: lead

NCT02889861Phase 2Terminated

IMCgp100-401 Rollover Study

Role: lead

NCT01211262Phase 1Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Role: lead

All 20 trials loaded